Global Alzheimer Disease Research Report 2021: Updated Report with Focus on New Drugs, Markets and Competitive Landscape, 2020-2030 - ResearchAndMarkets.com
Profiles of 117 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 89 collaborations.
The "Alzheimer Disease - New Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
Profiles of 117 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 89 collaborations. The bibliography contains over 900 publications that are cited in the report. The report is supplemented with 48 tables and 27 figures.
Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure.
The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.
Early diagnosis of Alzheimer's disease is an important first step in management. Several biomarkers in cerebrospinal fluid, blood and urine can detect the disease. They provide a valuable aid to the clinical examination and neuropsychological testing which are the main diagnostic methods supplemented by brain imaging. Genotyping, particularly of ApoE gene alleles is also useful in the evaluation of cases and planning management.
The current management of Alzheimer's disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly asymptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer's disease is being recognized.
Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.
Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Ongoing as well as discontinued clinical trials of AD are tabulated.
Alzheimer's disease market in the seven major markets is analyzed for the year 2020. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2030. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.
The report contains information on the following:
- Clinical features, epidemiology, and pathology of Alzheimer disease
- Diagnostic procedures for Alzheimer's disease
- Management of Alzheimer's disease
- Research in Alzheimer's disease
- Drug discovery and development for Alzheimer's disease
- Marketing and financial aspects of Alzheimer's disease
- Companies
For more information about this report visit https://www.researchandmarkets.com/r/ejmokk
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005411/en/